Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Cancer Related Cognitive Decline × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 563 Triple Negative Breast Neoplasms 146 Carcinoma, Non-Small-Cell Lung 91 Ovarian Neoplasms 89 Neoplasm Metastasis 64 Colorectal Neoplasms 59 Stomach Neoplasms 52 Melanoma 51 Neoplasms 50 Pancreatic Neoplasms 48 Squamous Cell Carcinoma of Head and Neck 46 Lung Neoplasms 43 Prostatic Neoplasms 41 Endometrial Neoplasms 40 Carcinoma, Renal Cell 33 Uterine Cervical Neoplasms 31 Head and Neck Neoplasms 31 Esophageal Neoplasms 29 Sarcoma 28 Breast Neoplasms, Male 27 Urinary Bladder Neoplasms 24 Small Cell Lung Carcinoma 22 Colonic Neoplasms 22 Carcinoma, Transitional Cell 21 Carcinoma, Ovarian Epithelial 19 Lymphoma 18 Brain Neoplasms 18 Liver Neoplasms 15 Carcinoma, Hepatocellular 15 Kidney Neoplasms 14

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡